Recursion Pharmaceuticals (NASDAQ: RXRX)
Business & Investment Update — August 19, 2026
Investment View: SPECULATIVE BUY / ACCUMULATE
Current price: approximately US$3.39
Market capitalization: approximately US$1.8 billion
Recursion Pharmaceuticals is entering an important stage in its evolution. For several years, investors were essentially being asked to believe that Recursion's enormous biological datasets, machine-learning models and automated laboratories would eventually produce better drugs faster and more cheaply than conventional pharmaceutical discovery. In 2026, we are beginning to see evidence that this may actually be happening.
What's New
The most significant recent development is Genentech's decision to exercise its first Validated Target Option under the Roche/Genentech neuroscience collaboration. The target—previously unexplored in neuroscience—was discovered and experimentally validated using Recursion's AI-native platform and is now advancing into a joint small-molecule discovery program.
This is important validation from one of the world's premier drug-development organizations. Recursion has now received $216 million in upfront and milestone payments from Roche/Genentech. The collaboration potentially encompasses as many as 40 small-molecule programs, with each carrying more than $300 million of potential development, commercialization and sales milestones plus royalties. These figures represent potential contractual economics, not guaranteed future revenue.
The Sanofi partnership is also advancing. Recursion and Sanofi are progressing AI-designed molecules in immunology/inflammation and oncology toward development-candidate milestones. Recursion has received approximately $134 million in upfront and milestone payments from Sanofi, with individual programs potentially carrying another $343 million in milestones plus tiered double-digit royalties.
The Drug Pipeline
The most important near-term internal program is REC-4881, being developed for Familial Adenomatous Polyposis (FAP), a rare inherited condition associated with extensive gastrointestinal polyps and colorectal-cancer risk.
The FDA has already granted REC-4881 Fast Track and Orphan Drug designations. Recursion has initiated discussions with the FDA about a potential registrational pathway, and additional Phase 2 results are scheduled for presentation November 2, 2026.
That could be one of the most important RXRX catalysts of the year.
A second program worth watching is REC-7735, a highly selective PI3Kα H1047R inhibitor for cancer. Its IND has been cleared and a Phase 1/2 trial is expected to begin during the second half of 2026. Recursion reports greater than 100-fold selectivity for the cancer-associated mutant versus wild-type PI3Kα.
Other clinical programs—including REC-1245, REC-617, REC-3565 and REC-4539—give Recursion multiple additional shots on goal rather than leaving shareholders dependent upon one drug.
Financial Position
The financial picture remains the principal reason RXRX should be considered speculative.
For Q2 2026, Recursion reported approximately $7.7 million of revenue, $89.6 million of R&D expense, $41.5 million of G&A expense and a $131 million net loss. It ended June with approximately $557 million of cash and restricted cash.
The positive development is expense control. Management reduced expected 2026 cash operating expenses to less than $375 million, versus its previous guidance of less than $390 million, and continues to indicate a cash runway into early 2028.
Nevertheless, investors should assume that additional capital—and therefore potentially additional share dilution—will eventually be required unless partnership payments, licensing transactions or other funding materially improve the equation.
Why RXRX Is Interesting Now
The investment thesis has subtly changed.
RXRX is no longer simply a bet that "AI will revolutionize drug discovery." Investors now have three potential sources of value:
1. Proprietary drugs — REC-4881, REC-7735, REC-1245 and the broader clinical pipeline.
2. The Recursion platform — AI, biological mapping, automated experimentation and precision chemistry that could potentially shorten and improve conventional drug discovery.
3. Pharmaceutical partnerships — Roche/Genentech and Sanofi provide external validation while giving Recursion access to milestone payments and eventual royalties without financing every drug itself.
Genentech advancing a novel neuroscience target discovered through the platform is particularly important because it begins converting the Recursion OS story from theoretical capability into pharmaceutical-industry validation.
How we are approaching an Investment Today
At approximately $3.39, RXRX remains close enough to the depressed end of its historical range that we believe the risk/reward has become attractive for aggressive growth investors. The stock remains far below its 52-week high despite improving platform validation and a growing number of clinical catalysts.
We would not purchase a full position immediately.
For an intended $10,000 RXRX position, our preferred approach would be approximately:
- $4,000 now around current levels.
- $3,000 on weakness toward roughly $3.00–$3.15, if the fundamental thesis remains intact.
- $3,000 reserved for confirmation, particularly around REC-4881/FDA developments and the November clinical-data presentation.
We would rather pay somewhat more for the final tranche after positive clinical confirmation than commit all of the capital before a binary biotechnology catalyst.
What Could Go Right
If REC-4881 produces convincing additional Phase 2 results, the FDA provides a workable registrational pathway, REC-7735 enters clinical development successfully, and Roche/Genentech or Sanofi advances additional AI-discovered programs, the market could begin valuing Recursion as something substantially more valuable than today's approximately $1.8-billion company.
The real upside case isn't one successful drug. It is proof that Recursion can repeatedly discover better drug candidates faster than conventional pharmaceutical R&D. If that becomes demonstrable, the platform itself could become enormously valuable.
What Could Go Wrong
This remains biotechnology. Clinical failures are entirely possible. Revenue remains tiny relative to operating expenses, cash burn is substantial, commercialization is years away, and further equity issuance could dilute existing shareholders.
There is also an important technology risk: producing promising molecules more efficiently does not guarantee successful Phase 2/3 trials or regulatory approvals.
Investment Conclusion
RXRX remains one of the more interesting high-risk/high-potential companies at the intersection of artificial intelligence and biotechnology.
What makes the stock more attractive in August 2026 is that the company's scientific and commercial story appears to be improving while its valuation remains depressed.
The Genentech development is particularly significant. A sophisticated pharmaceutical partner has taken a novel target generated and validated through Recursion's system and committed it to an actual drug-discovery program. Sanofi's programs are progressing as well, while Recursion's proprietary pipeline is generating several potentially meaningful catalysts.
We therefore rate RXRX a Speculative Buy/Accumulate, but recommend building the position in stages rather than making a single large purchase.
For investors willing to accept biotechnology-level risk, the approximately $3–$3.50 area represents an attractive accumulation zone in our view. The November REC-4881 data and subsequent FDA guidance could determine whether RXRX remains a speculative AI-biotech story—or begins evolving into something considerably more valuable.
Risk Rating: High
Investment Horizon: 2–5 years
Strategy: Accumulate gradually; maintain capital for post-clinical-data confirmation.
